ACM
ANIK icon

Archon Capital Management’s Anika Therapeutics ANIK Stock Holding History

Archon Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-48,925
Closed -$2.21M – 35
2020
Q4 		$2.21M Buy
+48,925
New +$1.86M 0.38% 27

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Boston Trust Walden
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Fort Washington Investment Advisors
Fort Washington Investment Advisors Cincinnati, Ohio $19.7B AUM 20.11% 1-Year Est. Return

Archon Capital Management's ANIK Position: Q1 2021 in Review

Archon Capital Management sold out of Anika Therapeutics (ANIK) in Q1 2021, closing a stake of 48,925 shares — an estimated $2.21M sold.

Archon Capital Management first reported a position in ANIK in Q4 2020 and held it in 1 quarter. The position peaked at $2.21M in Q4 2020. 145 funds tracked by Wall St. Rank hold ANIK as of Q1 2021.

  • Archon Capital Management reported no remaining Anika Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Archon Capital Management sold 48,925 Anika Therapeutics shares in Q1 2021, an estimated $2.21M.
  • Archon Capital Management first reported a position in Anika Therapeutics in Q4 2020 and held it in 1 quarter.
  • Archon Capital Management's Anika Therapeutics position peaked at $2.21M in Q4 2020.
  • 145 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2021.

Based on Archon Capital Management's 13F filing for Q1 2021, filed 14 May 2021.